Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Issue : The Pharmaceutical Journal, 7 February 2015, Vol 294, No 7848

Sort by: Newest first Oldest first A-Z Z-A

  • Seth Berkley, chief executive officer of GAVI Alliance which brings together public and private sectors to bring new and underused vaccines for children living in poor countries

    Q&A: Getting life-saving vaccines to children in poor countries Subscription

    3 FEB 2015 9:52 By John Zarocostas

    Gavi, the Vaccine Alliance, brings together public and private sectors to deliver new and underused vaccines for children living in poor countries. Seth Berkley, its chief executive officer, discusses the current challenges to increase immunisation coverage in poor countries.

  • Translocator proteins (TSPO) pair up: each protein contains five helices that can bind to porphyrins, as well as PK11195 and cholesterol.

    Structure of translocator protein hints at role in disease Subscription

    2 FEB 2015 17:37 By Mark Peplow

    Two research groups have independently solved the structures of similar translocator proteins, offering clues about its function that could spur the development of targeted drugs.

  • UK government provides £13.7m for ‘stratified medicine’ collaborations Subscription

    2 FEB 2015 17:23

    The UK government has announced £13.7m of funding for four ‘stratified medicine’ collaborations with the Medical Research Council.

  • Cholic acid named ‘Golden Pill’ in Prescrire’s annual awards Subscription

    2 FEB 2015 16:44

    ‘A drug used to treat children with a rare genetic condition who are unable to produce bile and risk fatal liver failure has received international recognition.

  • Tribute to Peter West Subscription

    2 FEB 2015 12:28 By Angela West

    Peter worked and tutored a range of pharmacy disciplines in Huddersfield Royal, Seacroft Hospital, St James’ Teaching Hospital and Battle Hospital, Reading, before becoming staff pharmacist at the Royal Hallamshire in Sheffield.

  • Calcium-Sandoz syrup discontinued

    30 JAN 2015 17:04

    Calcium-Sandoz Syrup (calcium glubionate 1.09g and calcium lactobionate 0.727g per 5ml) has been discontinued in the UK by Alliance Pharmaceuticals and there is no remaining stock available. Calcium-Sandoz Syrup has not been readily available in the UK for over one year due manufacturing issues that have been unable to be resolved. Further information on +44 (01)249 466966. 

  • Erivedge side effects updated Subscription

    30 JAN 2015 16:41

    The summary of product characteristics of Erivedge (vismodegib; Roche) has been updated to reflect a change in frequency values for some of the most common adverse drug reactions (alopecia, dysgeusia, weight decreased and fatique). Diarrhoea has also been added to this section. The adverse reactions table has been updated to reflect ...

  • Lipid modification learning tool

    30 JAN 2015 16:40

    The National Institute for Health and Care Excellence (NICE) has launched a new online learning tool – Lipid modification. Developed by the Centre for Pharmacy Postgraduate Education, the tool supports the implementation of NICE guideline 181, called Lipid modification. It is available from the

  • Electronic safety update repository launched by EMA

    30 JAN 2015 16:39

    An electronic repository for periodic safety update reports (PSURs) and their assessment reports has been launched by the European Medicines Agency (EMA). The central platform was created in accordance with the pharmacovigilance legislation of the European Union (EU) and will contain all information related to PSURs in the EU. It will facilitate the assessment of PSURs by medicines ...

  • Eculizumab approved by NICE Subscription

    30 JAN 2015 16:37

    The National Institute for Health and Care Excellence approved the use of eculizumab (Soliris) for the treatment of atypical haemolytic uraemic syndrome (aHUS) for NHS patients in England on 27 January 2015. But conditions were attached: the product should be made available through an expert centre, the number of people diagnosed with aHUS and those being treated with eculizumab must be recorded and monitored, a national clinical protocol should be established for starting and stopping ...

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.